Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLXNASDAQ:ETNBNYSE:OGNNASDAQ:PTCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$53.77-7.7%$64.11$47.86▼$107.37$3.02B0.34578,176 shs521,945 shsETNB89bio$7.99+2.4%$7.24$4.16▼$11.84$1.16B1.231.36 million shs1.17 million shsOGNOrganon & Co.$8.23-2.5%$12.63$8.05▼$23.10$2.14B0.753.10 million shs1.26 million shsPTCTPTC Therapeutics$46.20-0.4%$48.62$28.72▼$58.38$3.65B0.52853,277 shs66,271 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx-2.10%+10.39%-1.52%-7.99%+17.04%ETNB89bio-3.82%+0.65%+41.05%-29.16%-10.34%OGNOrganon & Co.-3.01%-7.87%-24.50%-42.65%-59.76%PTCTPTC Therapeutics+0.83%+28.18%+7.93%-5.19%+46.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACLXArcellx1.6734 of 5 stars3.50.00.00.02.72.50.0ETNB89bio3.0196 of 5 stars4.51.00.00.04.00.80.6OGNOrganon & Co.4.9123 of 5 stars3.02.03.33.73.23.33.1PTCTPTC Therapeutics4.2563 of 5 stars4.33.00.04.42.50.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.07Buy$111.33107.05% UpsideETNB89bio 3.00Buy$27.25241.14% UpsideOGNOrganon & Co. 2.00Hold$18.00118.84% UpsidePTCTPTC Therapeutics 2.67Moderate Buy$61.9234.03% UpsideCurrent Analyst Ratings BreakdownLatest ETNB, PTCT, OGN, and ACLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/10/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/9/2025ACLXArcellxScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$133.00 ➝ $93.005/9/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$55.00 ➝ $68.005/8/2025PTCTPTC TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.005/7/2025PTCTPTC TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$57.00 ➝ $58.005/7/2025PTCTPTC TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$70.00 ➝ $66.005/7/2025PTCTPTC TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$113.00 ➝ $112.005/7/2025PTCTPTC TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $67.005/7/2025PTCTPTC TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSell ➝ Neutral$50.00 ➝ $40.005/5/2025OGNOrganon & Co.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $10.005/2/2025OGNOrganon & Co.Evercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Inline(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$76.81M38.55N/AN/A$9.97 per share5.39ETNB89bioN/AN/AN/AN/A$5.75 per shareN/AOGNOrganon & Co.$6.29B0.34$2.64 per share3.12($0.27) per share-30.46PTCTPTC Therapeutics$1.77B2.07$2.22 per share20.80($10.85) per share-4.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$70.69M-$2.99N/AN/AN/A-25.94%-8.28%-5.21%N/AETNB89bio-$142.19M-$3.38N/AN/AN/AN/A-59.58%-52.21%N/AOGNOrganon & Co.$864M$2.882.472.200.9013.49%431.62%8.03%N/APTCTPTC Therapeutics-$626.60M$6.51N/AN/AN/A-50.32%N/A-16.44%N/ALatest ETNB, PTCT, OGN, and ACLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ACLXArcellx-$0.84-$1.13-$0.29-$1.13$19.51 million$8.13 million5/6/2025Q1 2025PTCTPTC Therapeutics$0.85$10.04+$9.19N/A$437.16 million$1.18 billion5/1/2025Q1 2025ETNB89bio-$0.50-$0.49+$0.01-$0.49N/AN/A5/1/2025Q1 2025OGNOrganon & Co.$0.89$1.02+$0.13$0.33$1.53 billion$1.51 billion3/6/2025Q4 2024ETNB89bio-$0.60-$1.02-$0.42-$1.02N/AN/A2/27/2025Q4 2024ACLXArcellx-$0.63-$0.87-$0.24-$0.87$27.42 million$15.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AETNB89bioN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.97%+25.99%2.78%N/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ALatest ETNB, PTCT, OGN, and ACLX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025OGNOrganon & Co.quarterly$0.020.8%5/12/20255/12/20256/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.294.29ETNB89bio0.0911.6611.66OGNOrganon & Co.17.731.701.21PTCTPTC TherapeuticsN/A2.102.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%ETNB89bioN/AOGNOrganon & Co.77.43%PTCTPTC TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipACLXArcellx6.24%ETNB89bio2.60%OGNOrganon & Co.1.96%PTCTPTC Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.07 million50.70 millionOptionableETNB89bio40145.98 million103.15 millionOptionableOGNOrganon & Co.10,000259.96 million253.93 millionNot OptionablePTCTPTC Therapeutics1,41079.26 million72.88 millionOptionableETNB, PTCT, OGN, and ACLX HeadlinesRecent News About These CompaniesLost Money on PTC Therapeutics, Inc. (PTCT)? Possible Fraud - Contact Levi & Korsinsky TodayMay 14 at 10:30 AM | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against PTC Therapeutics, Inc. (PTCT) and Encourages Investors to Learn More About the InvestigationMay 14 at 10:00 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTMay 14 at 9:00 AM | accessnewswire.comJacobs Levy Equity Management Inc. Sells 659,778 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)May 14 at 5:58 AM | marketbeat.comDid PTC Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - PTCTMay 13 at 12:25 PM | accessnewswire.comShareholders that lost money on PTC Therapeutics, Inc. (PTCT) should contact Levi & Korsinsky about Securities Fraud Investigation - PTCTMay 13 at 10:15 AM | accessnewswire.comPTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationMay 13 at 10:00 AM | accessnewswire.comNorthern Trust Corp Grows Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)May 13 at 4:17 AM | marketbeat.comInvestors Who Lost Money on PTC Therapeutics, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - PTCTMay 12 at 5:30 PM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTMay 12 at 5:07 PM | prnewswire.comShareholders that lost money on PTC Therapeutics, Inc. (PTCT) should contact Levi & Korsinsky about Securities Fraud Investigation - PTCTMay 12 at 10:30 AM | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Is Investigating PTC Therapeutics, Inc. (PTCT) And Encourages Investors to ConnectMay 12 at 10:00 AM | accessnewswire.comBrevan Howard Capital Management LP Takes $551,000 Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)May 12 at 4:45 AM | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Upgraded to "Buy" at Bank of AmericaMay 12 at 1:44 AM | americanbankingnews.comPTC Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- PTCTMay 11 at 11:00 AM | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Is Investigating PTC Therapeutics, Inc. (PTCT) And Encourages Stockholders to ConnectMay 11 at 10:00 AM | accessnewswire.comPTC Therapeutics (NASDAQ:PTCT) Rating Increased to Buy at Bank of AmericaMay 11 at 8:51 AM | marketbeat.comLeerink Partnrs Has Bullish Forecast for PTCT Q1 EarningsMay 11 at 8:11 AM | marketbeat.comWilliam Blair Lifts Earnings Estimates for PTC TherapeuticsMay 11 at 8:11 AM | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by Cubist Systematic Strategies LLCMay 11 at 6:23 AM | marketbeat.comCantor Fitzgerald Issues Positive Estimate for PTCT EarningsMay 11 at 2:39 AM | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeETNB, PTCT, OGN, and ACLX Company DescriptionsArcellx NASDAQ:ACLX$53.77 -4.48 (-7.69%) As of 10:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.89bio NASDAQ:ETNB$7.99 +0.19 (+2.41%) As of 10:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Organon & Co. NYSE:OGN$8.22 -0.22 (-2.55%) As of 10:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.PTC Therapeutics NASDAQ:PTCT$46.20 -0.19 (-0.41%) As of 10:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oklo Reaches Critical Mass, Atomic Upside Still Available U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer NVIDIA Stock Surges on Bullish News: How High Could It Climb? ON Holding Surges, Leads High-End Retailers Into Reversal D-Wave Pushes Back on Short Seller Case With Strong Earnings NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
